Loading
Loading
Metabolic & Body Composition · 10mg
Janoshik-tested · 10 vials per kit
Mazdutide is a dual GLP-1 and glucagon receptor agonist studied in preclinical and clinical research for its metabolic effects. Research has examined its potential to promote insulin secretion, suppress appetite, enhance lipolysis, increase energy expenditure, and reduce liver fat accumulation. Studies have also explored positive effects on hyperuricemia, blood pressure regulation, and cardiovascular protection.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Mazdutide
GLP-1/Glucagon Dual Receptor Agonist
Mazdutide (IBI362 / GLXC-26803) is a synthetic GLP-1/glucagon dual receptor agonist developed by Innovent Biologics. It is a long-acting peptide with a fatty acid modification enabling once-weekly subcutaneous administration. Phase III clinical trials are underway in China for obesity and type 2 diabetes, with data showing weight reduction exceeding semaglutide at comparable timepoints.
Mazdutide simultaneously activates GLP-1 receptors (appetite suppression, glucose-dependent insulin secretion, slowed gastric emptying) and glucagon receptors (hepatic energy expenditure, thermogenesis, lipolysis). The dual mechanism addresses both caloric intake via GLP-1R and energy expenditure via GcgR — a combination that may produce superior outcomes compared to GLP-1 monoagonism. Hepatic glucagon receptor activation also reduces hepatic steatosis, making mazdutide a candidate for NAFLD/NASH.
Phase 2 data in Chinese adults with obesity demonstrated dose-dependent weight reduction up to 13.9% at 24 weeks — exceeding semaglutide's performance at equivalent timepoints in the same population. Liver fat reduction, lipid profile improvement, and waist circumference changes were documented. Phase III trials are evaluating cardiovascular outcomes and HbA1c reduction in type 2 diabetes.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
